Intensive Care Medicine

, Volume 22, Issue 10, pp 1093–1095

The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide

  • S. Al-Alaiyan
  • A. Al-Omran
  • D. Dyer
Brief Report

Abstract

A full-term, male neonate developed persistent pulmonary hypertension, and responded to high-frequency oscillatory ventilation and inhaled nitric oxide (INO). Discontinuation of INO was attempted three times and was followed by severe desaturations due to right-to-left shunt through the patent ductus arteriosus and patent foramen ovale. As a result of this rebound pulmonary hypertension, the neonate was maintained on INO therapy for 6 days. Successful discontinuation was achieved by using the phosphodiesterase inhibitor, dipyridamole. We speculate that during exogenous INO therapy, endogenous nitric oxide was inhibited, thus cyclic guanosine 3′,5′-monophophate, the smooth muscle relaxant, was rapidly hydrolyzed. By inhibiting phosphodiesterase, smooth muscle relaxation occurred, and consequently weaning from INO was achieved.

Key words

Neonates Phosphodi-esterase inhibitor Nitric oxide Pulmonary hypertension 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kinsella JP, Neish SR, Dunbar I, Shaffer E, Abman SH (1993) Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 123: 103–108Google Scholar
  2. 2.
    Roberts JD, Polaner DM, Lang P, Zapol WM (1992) Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:818–819Google Scholar
  3. 3.
    Kinsella JP, Neish SR, Shaffer E, Abman SH (1992) Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340: 819–820Google Scholar
  4. 4.
    Griffith TM, Edwards DH, Lewis MJ, Henderson AH (1985) Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation. Eur J Pharmacol 112: 195–202Google Scholar
  5. 5.
    Bult H, De Meyer GRY, Jordaens FH, Herman AG (1991) Chronic exposure to exogenous nitric oxide may suppress its endogenous release and efficacy. J Cardiovasc Pharmacol 17 [Suppl 3]: S79-S82Google Scholar
  6. 6.
    Alfonso S, O'Brien GS (1971) Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs. Arch Int Pharmacodyn Ther 194: 181–196Google Scholar
  7. 7.
    Klabunder RE (1983) Effects of dipyridamole on post-ischemic vasodilatation and extracellular adenosine. Am J Physiol 244: H273-H280Google Scholar
  8. 8.
    Scharder JR, Berne M, Rubio R (1973) Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 223:159–166Google Scholar
  9. 9.
    Beavo JA, Reifsynder DH (1990) Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sci 11: 150–155Google Scholar
  10. 10.
    Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH (1995) Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilatation in the ovine fetus. Am J Physiol 269:H473-H479Google Scholar
  11. 11.
    Kinsella JP, Torielli F, Ziegler JW, Ivy DD, Abman S (1995) Dipyridamole augmentation of response to nitric oxide. Lancet 346: 647–648Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • S. Al-Alaiyan
    • 1
  • A. Al-Omran
    • 1
  • D. Dyer
    • 1
  1. 1.Neonatology Section, Department of Pediatrics (MBC 58)King Faisal Specialist Hospital and Research CentreRiyadhKingdom of Saudi Arabia

Personalised recommendations